Cannabinoid Hyperemesis Syndrome Management

Introduction to CHS

• The British Journal of Anaesthesia recommends that patients with cannabinoid hyperemesis syndrome (CHS) receive enhanced prophylactic antiemetic therapy perioperatively due to increased risk for post-anesthesia intractable vomiting 1

Pathophysiological Mechanism

• The endocannabinoid system's control over emesis is dysregulated in CHS, with CB1 receptors densely distributed in the dorsal vagal complex, a critical area for controlling emesis 2, 3, 4
• Chronic cannabis use leads to loss of negative feedback on the hypothalamic-pituitary-adrenal axis, resulting in increased vagal nerve discharges that contribute to vomiting 2, 5, 6
• Altered gastric motility and emptying occur through peripheral CB1 receptor activation 2, 7

Perioperative Management Algorithm

• The American Gastroenterological Association and British Journal of Anaesthesia recommend multimodal antiemetic prophylaxis for patients meeting high-risk cannabis consumption criteria, which differs from standard PONV protocols 1
• Prioritize butyrophenones, such as Haloperidol or droperidol, for their superior efficacy in reducing hospital length of stay by nearly 50% (6.7 vs 13.9 hours, p=0.014) 8
• Consider benzodiazepines for their sedating and anxiolytic effects, which address the stress-mediated component of CHS 5, 6
• Add topical capsaicin 0.1% applied to the abdomen, which activates TRPV1 receptors and has shown consistent benefit 5, 6, 8

Anesthetic Considerations

• Cannabis users may require higher doses of anesthetic agents to achieve adequate depth of anesthesia 1
• Consider using processed depth of anesthesia EEG monitoring (BIS) for patients with heavy cannabis use 1

Postoperative Pain Management

• Anticipate higher postoperative analgesic requirements in chronic cannabis users 1
• Avoid opioids as they worsen nausea and carry high addiction risk in this population 5, 6, 8
• Consider multimodal non-opioid analgesia strategies 1

Critical Diagnostic Pitfalls

• CHS is frequently underdiagnosed or misdiagnosed due to limited clinician awareness, leading to extensive unnecessary testing 8, 7, 9
• Rule out life-threatening conditions first (acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, myocardial infarction) before attributing symptoms solely to CHS 6, 8

Definitive Management

• Cannabis cessation is the only definitive treatment for CHS and should be strongly recommended preoperatively when feasible 5, 6, 8, 9
• Tricyclic antidepressants, such as amitriptyline, are the mainstay of preventive therapy for long-term management 5, 6, 9

Cannabinoid Hyperemesis Syndrome Associated with Edible Cannabis Consumption

Introduction to CHS

• Edible cannabis consumption can cause Cannabinoid Hyperemesis Syndrome (CHS), as the syndrome is triggered by chronic exposure to THC regardless of the route of administration, with the total THC dose and duration of use being the critical factors, not the method of consumption, according to the American Gastroenterological Association 10

Clinical Presentation and Diagnosis

• Suspect CHS in patients presenting with stereotypical episodic vomiting, at least 3 episodes annually, with acute onset and duration less than 1 week, as recommended by the American Gastroenterological Association 10
• Pathognomonic hot water bathing behavior, compulsive use of hot showers or baths for symptom relief, is observed in 44% of CHS patients, as noted by the American Gastroenterological Association 10

Risk Factors and Prevention

• Prolonged high-dose THC exposure, not the delivery method, is the critical factor in developing CHS, and edibles deliver THC systemically just as effectively as smoking or vaping, according to the American Gastroenterological Association 10
• Modern cannabis products, including edibles, contain dramatically higher THC concentrations than historical products, increasing the risk of CHS, as reported by the American Gastroenterological Association 10

Diagnostic Criteria for Cannabinoid Hyperemesis Syndrome

Key Diagnostic Features

• The American Gastroenterological Association suggests that complete and persistent resolution of all symptoms after cannabis cessation for at least 6 months is the only reliable diagnostic criterion that separates Cannabinoid Hyperemesis Syndrome (CHS) from Cyclical Vomiting Syndrome (CVS) 11, 12, 13
• CHS requires specific cannabis exposure criteria, including duration of cannabis use >1 year before symptom onset and frequency of use >4 times per week on average, as recommended by the American Gastroenterological Association 11, 12, 13
• Both CHS and CVS present identically with stereotypical episodic vomiting occurring ≥3 times annually, according to the American Gastroenterological Association 11, 12, 13
• Hot water bathing behavior is present in 71% of CHS patients, but also reported in 44% of CVS patients, and does not reliably distinguish between the two syndromes, as noted by the American Gastroenterological Association 11, 12, 13
• Complete symptom resolution after 6 months of abstinence confirms CHS, as stated by the American Gastroenterological Association 11, 12, 13

Diagnostic Algorithm

• The American Gastroenterological Association recommends a diagnostic algorithm that includes establishing cannabis use pattern, assessing clinical features, evaluating hot water bathing behavior, looking for CVS-specific supportive features, and implementing a therapeutic trial 11, 12, 13
• In the acute setting, both conditions require exclusion of life-threatening disorders first, such as acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction, as recommended by the American Gastroenterological Association 11, 12, 13

Management Approach

• The American Gastroenterological Association suggests that for suspected CHS, counseling strongly for cannabis cessation is both diagnostic and the only definitive treatment 11, 12, 13
• Acute symptom management includes topical capsaicin 0.1%, haloperidol, benzodiazepines, or promethazine, and avoiding opioids as they worsen nausea, as recommended by the American Gastroenterological Association 11, 12, 13

Diagnostic Criteria for Cyclic Vomiting Syndrome and Cannabis Hyperemesis Syndrome

Diagnostic Framework

• The American Gastroenterological Association recommends that complete and persistent resolution of all symptoms after at least 6 months of continuous cannabis abstinence is the gold standard diagnostic criterion to distinguish CHS from CVS 14
• Daily cannabis use occurred in 68% of confirmed CHS cases, according to the American Gastroenterological Association 14
• Hot water bathing behavior is present in 71% of CHS patients, but also reported in 44% of CVS patients, making it an unreliable distinguishing feature, as stated by the American Gastroenterological Association 14

Therapeutic Approach

• The American Gastroenterological Association suggests that topical capsaicin 0.1% cream applied to the abdomen can be used as an adjunct in acute management 14
• The American Gastroenterological Association recommends avoiding opioids entirely in the treatment of CHS and CVS, as they worsen nausea and carry high addiction risk 14

Long-Term Management

• The American Gastroenterological Association states that cannabis cessation remains the only definitive treatment for CHS, and tricyclic antidepressants (amitriptyline 75-100 mg at bedtime) can be used for prevention 14
• The American Gastroenterological Association recommends that standard CVS management protocols apply if CVS is diagnosed, with amitriptyline remaining the mainstay of preventive therapy 14